NCT05918302 2026-03-06
LEVEL
Grupo Espanol de Tumores Neuroendocrinos
Phase 3 Recruiting
Clinical Trials
35 trialsNCT06822751 2026-02-17
FOMUTI
University Hospital, Rouen
Phase 3 Not yet recruiting
NCT06937905 2026-02-11
TARLANEC
Intergroupe Francophone de Cancerologie Thoracique
Phase 3 Recruiting
NCT04706910 2026-02-09
18F-DOPA II - PET Imaging Optimization
University of Alberta
Phase 3 Recruiting
NCT06881992 2025-12-30
Tumor HI
Rezolute
Phase 3 Recruiting
NCT05387603 2025-09-10
START-NET
Lund University Hospital
Phase 3 Recruiting
NCT06878664 2025-09-02
RIALTO
Grupo Espanol de Tumores Neuroendocrinos
Phase 3 Recruiting
NCT02010957 2025-06-10
FAMIAN
Wuerzburg University Hospital
Phase 3 Terminated
NCT02246127 2025-05-11
SEQTOR
Grupo Espanol de Tumores Neuroendocrinos
Phase 3 Completed
NCT06791005 2025-01-24
A Clinical Study on the Benefits of Carbon Nanoparticles Injection Time in Patients With Thyroid Cancer.
Second Affiliated Hospital of Xi'an Jiaotong University
Phase 3 Recruiting
NCT03723941 2024-08-01
ACACIA
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase 3 Completed
NCT04847505 2024-07-18
68Ga-DOTA-TATE PET/CT Imaging in NETs
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Phase 3 Recruiting
NCT03176693 2023-11-20
Preoperative Alpha Blockade for Pheochromocytoma
University of California, Los Angeles
Phase 3 Completed
NCT01837745 2023-05-17
ESTIMABL2
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Active not recruiting
NCT03136328 2023-05-09
Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan
Montefiore Medical Center
Phase 3 Completed
NCT03048877 2023-04-12
Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer
Peking Union Medical College Hospital
Phase 3 Unknown
NCT01842165 2022-11-10
LUMEN
Jules Bordet Institute
Phase 3 Completed
NCT02419664 2022-03-31
Ga-68-DOTATOC -PET in the Management of Pituitary Tumours
Göteborg University
Phase 3 Terminated
NCT03042416 2022-01-10
18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety
University of Alberta
Phase 3 Completed
NCT00171873 2020-03-26
Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut
Philipps University Marburg
Phase 3 Completed
NCT02358226 2020-02-17
HIV & Drug Abuse Prevention for South African Men
University of California, Los Angeles
Phase 3 Completed
NCT00037869 2018-10-31
High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00227136 2018-04-13
Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion
Western University, Canada
Phase 3 Terminated
NCT03439709 2018-03-01
MERGE
Samsung Medical Center
Phase 3 Unknown
NCT03271918 2017-09-07
Cabergoline in Nonfunctioning Pituitary Adenomas
University of Sao Paulo General Hospital
Phase 3 Completed
NCT00777244 2017-05-08
ADIUVO
University of Turin, Italy
Phase 3 Unknown
NCT00094497 2016-09-21
Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)
Collaborative Group for Adrenocortical Carcinoma Treatment
Phase 3 Completed
NCT01755182 2016-05-06
LOTUS
National Cancer Institute, Naples
Phase 3 Terminated
NCT00795782 2016-04-15
Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma
Samsung Medical Center
Phase 3 Completed
NCT01860742 2016-04-05
CASTOR
Jules Bordet Institute
Phase 3 Withdrawn
NCT01096654 2015-07-16
SPARTACUS
Radboud University Medical Center
Phase 3 Completed
NCT00314028 2013-12-16
Effectiveness of HIV Risk Reduction Program Among African American Men
University of Kentucky
Phase 3 Completed
NCT00767338 2013-07-02
VIA
Yale University
Phase 3 Terminated
NCT00037843 2012-02-22
Iodine I-131 Iodocholesterol, Its Use in Adrenal Screening
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00889525 2009-04-29
Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor
Seth Gordhandas Sunderdas Medical College
Phase 3 Completed